As reported by Mehr News Agency, the achievement of the biologists of California University in San Diego in using seaweed for generating a medicine for treatment of cancer, has been published in the Journal of “Articles of National Academy of Sciences” and has opened doors for generating this protein and other proteins in more and cheaper quantities.
Stephan Mifield, Professor of Biology of California University in San Diego and Head of Center of San Diego Seaweed Biotechnology Center, as a research Institute, working on generating of biological fuel from seaweed, stated: “Since we generate the said medicine using the said seaweed, it is possible to decease its protraction cost accordingly”.
This method may be used for more advanced and modern plans of medicine so that the said medicines will be used for treatment of cancer and other forms of human diseases in new forms.
He further added: “The said medicines can’t be generated from bacterium because bacteria lack bending proteins: in three-dimensional complicated forms. Moreover, said proteins can’t be generated from cells of mammals because poison will damage the same.  
This achievement has been obtained pursuant to seven years of working at laboratory in order to find that “Chlamydomonas Reinhardt” is a kind of green seaweed, which is mainly used in biological laboratories is a genetic model of organism, which may generate a wide range of medical proteins used for humans, at remarkable quantities and even at low cost compared to bacteria and cells of mammals.
Mayfield et al have achieved the first progress five years ago. At that time, they could generate Amyloid protein serum from seaweed. One year later, said researchers could obtain a human antibody protein from seaweed and in 2010, they showed that a more complicated protein, which is used as a human medicine for treatment of patients, suffering from pulmonary Emphysema, may be obtained from seaweed accordingly.
As their latest achievement, the said scientist could generate a three dimensional and complicated protein with domain benefiting from seaweed genetic engineering. One of the said domains contains one antibody, which is joined to carcinoma cells and another domain contains a poison, which limits cancer cells.
Presently, this protein fusion, which has been done from seaweed by scientists at laboratory is a complicated process, which is being generated by pharmaceutical companies, spending over 100,000.- Dollars for this purpose. However, since the said protein has been generated from seaweed in laboratory, it may  be possible to decrease respective costs accordingly.